GPI SpA ( (IT:GPI) ) just unveiled an update.
GPI S.p.A. announced the resignation of Executive Director Sergio Manzana, who is stepping down to focus on his role as President of The Drug Cell, a joint venture in France. Andrea Di Santo has been appointed as the new Director and member of the Strategic Committee. The company has also scheduled a Shareholders’ Meeting for April 29, 2025, to discuss financial statements, board appointments, and other corporate matters.
More about GPI SpA
GPI S.p.A. is a leader in the digital transformation of healthcare, focusing on making healthcare systems sustainable and providing quality care through innovative software, technologies, and services. With over 7,600 employees, the company generated €433 million in revenues in 2023, serving more than 9,000 clients in 70 countries. GPI is listed on the Euronext Tech Leaders segment of Borsa Italiana.
YTD Price Performance: -22.21%
Average Trading Volume: 28,049
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €245.1M
Learn more about GPI stock on TipRanks’ Stock Analysis page.